Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Niraparib and abiraterone acetate + Prednisone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Niraparib and abiraterone acetate | Akeega | CJNJ-67652000|CJNJ 67652000|CJNJ67652000 | Hormone - Anti-androgens 48 PARP Inhibitor (Pan) 30 | Akeega (niraparib and abiraterone acetate) is a combination of Zejula (niraparib) and Zytiga (abiraterone). Akeega (niraparib and abiraterone acetate) in combination with Adasone (prednisone) is FDA-approved for use in patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious BRCA1/2 mutations (FDA.gov). |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05689021 | Phase II | Niraparib and abiraterone acetate + Prednisone | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Recruiting | USA | 0 |